image

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. Faculty disclosures can be found on each session page and Annual Meeting Steering Committee disclosures can be found here.



CLAIM CME OR RECEIVE CERTIFICATE OF PARTICIPATION:
Step 1: Starting June 15, visit https://education.endocrine.org/content/endo-online-2020-evaluation
Step 2: Log In (upper right corner of page).
Step 3: Click START to begin the evaluation. If you are looking for a certificate of participation and no credit, please complete the Participation Evaluation. If you are an MD/DO obtaining your AMA PRA Category 1 credit, you must complete the CME Evaluation where you will be asked to check all sessions you viewed and calculate your credits. You can only complete the evaluation once, so do not complete the evaluation until you have viewed all of the sessions for which you would like credit. The evaluation cannot be reopened to obtain additional credit.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body, along with the available program guide which notes the number of credits for each session.

Please note that the 90-minute ancillary symposia and 2020 Type 1 Diabetes Fellows session package have their own evaluations. Those links can be found on each individual session page under the Accreditation tab.

Learning Objectives:

Upon completion of this educational activity, learners will be able to

  • Discuss state-of-the-art research in endocrinology
  • Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae.
  • Apply updated knowledge and clinical skills in improving patient care.
  • Construct new research questions based on updated scientific and clinical advances in endocrinology-related disciplines

Continuing Medical Education
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. The Endocrine Society designates this live activity for a maximum of 23.75 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

European Accreditation Council for Continuing Medical Education
The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby:

European physicians attending an event in the USA had their credits recognized in Europe and American physicians attending an event in Europe had their credits recognized in the USA.

The Endocrine Society designates this educational activity for a maximum of 23.75 AMA PRA Category 1 Credit(s)™ for ENDO 2020. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Royal College of Physicians and Surgeons of Canada
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

DISCLAIMERS

  • USE OF PROFESSIONAL JUDGMENT: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
  • DRUGS AND DOSAGE: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications
  • POLICY ON UNLABELED/OFF-LABEL USE: The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events
  • PRIVACY AND CONFIDENTIALITY STATEMENT: The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties

Corporate Support
The Endocrine Society thanks the following supporters: 

  • Amarin Pharma, Inc.
  • Amryt Pharmaceuticals
  • Eisai, Inc.
  • Horizon Therapeutics USA, Inc.
  • Immunovant, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Medtronic Diabetes
  • Radius Health, Inc.
  • Strongbridge Biopharma U.S., Inc.
  • The Leona M. and Harry B. Helmsley Charitable Trust